People taking Hytrin (terazosin)or similar medications to treat high blood pressure and benign prostatic hyperplasiamay be less likely to develop Parkinsons disease, an early study suggests.
Parkinsons patients who use these medications may also see their disease progress more slowly and with fewer complications, its researchers report.
The study, Enhancing glycolysis attenuates Parkinsons disease progression in models and clinical databases, was published in the Journal of Clinical Investigation.
Hytrin is indicated for the treatment of non-cancerous prostate enlargement and high blood pressure (hypertension). The medication, available as a generic (terazosin), acts on the alpha-1 adrenergic receptor to block adrenalines action, relaxing smooth muscle in both the blood vessels and the prostate, allowing blood and urine, respectively, to flow more easily.
Experts agree that energy metabolism plays a central role in the molecular mechanism of neurodegenerative diseases like Parkinsons. In fact, problems in energy metabolism and low levels of cellular energy are common features of this disorder.
Hytrin has been shown to enhance the activity of a protein called phosphoglycerate kinase 1 (PGK1), which is involved in a critical energy-producing process known as glycolysis, where the simple sugar glucose is broken down by cells to produce energy. Boosting PGK1 activity increases the number of energy molecules, also known as ATP, within a cell.
Because low levels of ATP have been observed in Parkinsons, increasing the breakdown of glucose and hence cellular energy, in theory, may slow down or prevent the neurodegenerative processes underlying this disease.
Researchers at Capital Medical University in Beijing, decided to test this hypothesis and investigate whether increasing PGK1 activity levels would change the course of Parkinsons disease.
Hytrin was found to increase brain ATP levels and slow or prevent nerve cell loss in several models of Parkinsons (MPTP, rotenone and 6-OHDA-induced or genetic models): mice, rats, flies, and induced pluripotent stem cells. MPTP, rotenone and 6-OHDA are all neurotoxins that induce death of dopamine-producing neurons and mimic Parkinsons symptoms.
Treatment with this medication increased brain dopamine levels the chemical messenger that is present in low levels in the brains of Parkinsons patients and partially restored motor function in both mice and flies.
Importantly, boosting PGK1 activity was beneficial even when treatment was initiated after the onset of neurodegeneration, suggesting the modulation of this proteins function could help to slow Parkinsons progression.
Because Hytrin is prescribed for other diseases, scientists also studied two human databases the Parkinsons Progression Markers Initiative and the IBM Watson/Truven database looking for a possible Hytrin effect in relation to Parkinsons disease.
These two data sets included a total of 4,072 individuals on Hytrin, doxazosin, or alfuzosin. The latter two medications produce effects similar to those of Hytrin.
A retrospective analysis on both databases revealed that use of Hytrin and related agents slowed Parkinsons disease progression, reduced the number of neurodegeneration-related complications, and lessened the risk of a Parkinsons diagnosis, compared to people not using these medications.
These findings identify a protein and a pathway that might be targeted to slow or prevent neurodegeneration in PD [Parkinsons disease] and potentially other neurodegenerative diseases with altered energy balance, the researchers concluded.
Terazosin, available only by prescription, can cause dizziness and fainting because it lowers blood pressure.
With over three years of experience in the medical communications business, Catarina holds a BSc. in Biomedical Sciences and a MSc. in Neurosciences. Apart from writing, she has been involved in patient-oriented translational and clinical research.
- Kyoto University team gets OK from ministry for plan to transplant iPS-derived cartilage into knee joints - The Japan Times - January 25th, 2020
- The Kyoto University team's plan to transplant iPS cartilage into knee joints is OK - gotech daily - January 25th, 2020
- Get rid of the ache within the nerves discovered with the following pointers, learn - Sahiwal Tv - January 25th, 2020
- Astellas and Adaptimmune team up in CAR-T development - European Biotechnology - January 15th, 2020
- Stem Cell Therapy Market Rising Demand for Digitization in Organizations and Growth till 2027 - Galus Australis - January 15th, 2020
- Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines - Yahoo Finance - January 15th, 2020
- Researchers have managed to bio-print a functional mini-liver in 90 days - FLWL News - January 15th, 2020
- CYTOVIA Therapeutics and the New York Stem Cell Foundation Research Institute enter into a partnership to develop iPSC derived CAR NK Therapeutics -... - January 10th, 2020
- Stem Cells Market Segmentation and Analysis Report, 2025 - Food & Beverage Herald - January 10th, 2020
- Stem Cell Therapy Market Robust Growth Counted to 2025 - Instanews247 - January 10th, 2020
- The Top Biotech Trends We'll Be Watching in 2020 - Singularity Hub - January 10th, 2020
- Induced Pluripotent Stem Cells Market Structure, Industry Inspection, and Forecast 2025 - Filmi Baba - December 28th, 2019
- Top Technical Advances of 2019 - The Scientist - December 24th, 2019
- The next 3D-printing craze? It could be functioning 'mini-livers' - Inverse - December 24th, 2019
- Induced Pluripotent Stem Cells Market: Latest Innovations, Drivers and Industry Key Events 2016 2021 - Market Reports Observer - December 24th, 2019
- Stem Cell-Derived Cells Market Expected to Expand at a Steady CAGR through 2019 2029 - Downey Magazine - December 17th, 2019
- AgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells - Yahoo... - December 11th, 2019
- Patent Granted To Lineage & AgeX - Anti Aging News - December 11th, 2019
- Charles River Announces Strategic Partnership with Bit Bio, Increasing Portfolio of Translational Drug Discovery Technologies - BioSpace - December 11th, 2019
- Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting - GlobeNewswire - December 11th, 2019
- Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy - Benzinga - December 8th, 2019
- Induced Pluripotent Stem Cells Market Assessed To Tell Apart High Growth By Implies In 2018 to 2026 - Wolf Mirror - December 5th, 2019
- Kyoto University Seeking To Use Stem Cells On Knee Treatment - Anti Aging News - December 5th, 2019
- Story of a 15-year old scientist: How it all began - EuroScientist - December 5th, 2019
- Stemonix, Atomwise Team Up on Drug Discovery With MicroOrgans and AI - Xconomy - December 5th, 2019
- Channel in Nerve Cell May be Key in Unlocking Parkinson Disease Therapy - Pharmacy Times - December 3rd, 2019
- First-in-kind Human 3-dimensional Models of Parkinson's Disease and Progressive Multiple Sclerosis Launching to the International Space Station -... - December 3rd, 2019
- Stem Cells Market 2019 Global Growth Analysis and Forecast Report by 2025 - Markets Gazette 24 - November 26th, 2019
- UK animal experiment statistics indicate reluctance to embrace modern tools to advance British labs into the 21st century - Labmate Online - November 10th, 2019
- Human heart cells change during spaceflight, say scientists in study that could have far-reaching effects on c - MEAWW - November 7th, 2019
- Here's Why Fate Therapeutics Dropped as Much as 19.9% Today - Motley Fool - November 7th, 2019
- Space travel may change the human heart - Inverse - November 7th, 2019
- Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic... - November 5th, 2019
- Goldfinch Bio to Present Oral and Poster Presentations at the American Society of Nephrology Kidney Week 2019 Annual Meeting - BioSpace - November 5th, 2019
- MD Anderson and Takeda Team Up on Next-Generation Immuno-Oncology Therapeutics - BioSpace - November 5th, 2019
- Induced Pluripotent Stem Cell Market is expected to witness a strong CAGR of 7.0% from 2018 to 2026 - Zebvo - November 2nd, 2019
- Can organoids, derived from stem cells, be used in disease treatments? - The Hindu - October 26th, 2019
- University team to seek approval for iPS-based heart treatment trial - The Japan Times - October 26th, 2019
- Global Gemcitabine Hydrochloride Market: Segmented By Application And Geography Trends, Growth And Forecasts To 2024 - Health News Office - October 26th, 2019
- Global consortium formed to combat unproven cell banking services - Drug Target Review - October 22nd, 2019
- Bloomberg Philanthropies, Johns Hopkins University School of Medicine, and The New York Stem Cell Foundation Research Institute Announce an... - October 22nd, 2019
- ISCT forms cell and gene therapy sector-wide coalition to combat the rise of unproven commercial cell banking services - PharmiWeb.com - October 21st, 2019
- Mutations Linked to Huntington's Increase Cells' Resistance to Manganese, Study Finds - Huntington's Disease News - October 15th, 2019
- Stem Cells Market : Insights Into the Competitive Scenario of the Market - Online News Guru - October 11th, 2019
- 'Rewind Therapeutics' and Remyelination - SciTech Europa - October 11th, 2019
- Cell Expansion Market is expected to rise at a remarkable CAGR during the Forecast Period 2016 2024 - Space Market Research - October 9th, 2019
- Global Induced Pluripotent Stem Cells Market 2019 Innovative Trends and Insights Research upto 2024 - News Adopt - October 5th, 2019
- New Rett Therapies May Stem From X-chromosome Reactivation Findings - Rett Syndrome News - October 5th, 2019
- Stemming the Tide of Alzheimer's - UCI News - October 5th, 2019
- Skin-Derived Heart Cells Help Uncover the Genetic Foundations of Cardiac Function - Technology Networks - October 5th, 2019
- IGIB finds a protein with better precision in gene-editing - The Hindu - October 5th, 2019
- Novel Cell Sorting and Separation Market: Focus on Acoustophoresis, Buoyancy-activated, Dielectrophoresis, Magnetophoretics, Microfluidics,... - October 5th, 2019
- Fabry Heart Cells Grown in Lab Dish Give Hints to Cardiac Complications - Fabry Disease News - September 27th, 2019
- Global Induced Pluripotent Stem Cells (iPSCs) Market 2019 Analysis & Forecast Report 2024 - Analytics News - September 24th, 2019
- Gene regulators work together for oversized impact on schizophrenia risk - National Institutes of Health - September 24th, 2019
- New Gene Editing Technique Shown to Correct COL7A1 Gene in RDEB Cells - Epidermolysis Bullosa News - September 24th, 2019
- Vaginitis Therapeutics Market Overview with Detailed Analysis, Competitive lands - News By ReportsGO - September 24th, 2019
- Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Overview with Detailed - News by Intelligence Journal - September 24th, 2019
- Can Consciousness be Created? - University Observer Online - September 24th, 2019
- Global Induced Pluripotent Stem Cells (iPSCs) Market 2019 Industry Growth with CAGR 12.7% in Forecast to 2024 - Indian Columnist - September 21st, 2019
- Adipose Tissue-derived Stem Cells Market Size Set for Rapid Growth and Trend by2018 2028 - My Health Reporter - September 21st, 2019
- Induced Pluripotent Stem Cell Market Estimated to be Driven by Innovation and Industrialization - Analytics News - September 20th, 2019
- 2024 Projections: Induced Pluripotent Stem Cells (iPSCs) Market Report by Type, Application and Regional Outlook - TheSlapClap - September 20th, 2019
- Angelman Foundation Honors 4 for Their Research, Advocacy Efforts - Angelman Syndrome News - September 20th, 2019
- Dicerna And DCR-A1AT In Alpha-1 Antitrypsin Deficiency-Associated Liver Disease - Seeking Alpha - September 20th, 2019
- Fate Therapeutics raises $173 million in offering - The San Diego Union-Tribune - September 19th, 2019
- Induced Pluripotent Stem Cells Market is expected to reach US$ 2299.5 Mn by the end of the forecast period in 2026 - Zebvo - September 19th, 2019
- induced pluripotent stem cells (iPSCs) market reached $2.1 billion in 2016 The market should reach $3.6 billion in 2021 - ScoopJunction - September 19th, 2019
- Stem Cell-Derived Cells Market to Record an Exponential CAGR by 2025 - NewsVarsity - September 19th, 2019
- Common Prostate Drug May Slow Progression of Parkinson, Researchers Say - AJMC.com Managed Markets Network - September 19th, 2019
- Automated Large-Scale Production of Retinal Organoids - Advanced Science News - September 19th, 2019
- How a Centuries-Old Sculpting Method Is Helping 3D Print Organs With Blood Vessels - Singularity Hub - September 19th, 2019
- Study indicates early infusion of mononuclear cells could aid in recovery from stroke - Yahoo Finance - September 19th, 2019
- BIOLIFE4D Successfully 3D Bioprints a Miniature Human HeartOne Step Closer to Bioprinting Transplantable Organs - BioSpace - September 19th, 2019
- Scientists recognize genes as master regulators in schizophrenia - Tech Explorist - September 19th, 2019
- Japanese lab to collaborate with Christian Dior in iPS cell research - Japan Today - September 19th, 2019
- Induced Pluripotent Stem Cell Market Research Report 2019 From TBRC has Been Updated - Market Research Gazette - September 19th, 2019
- What are Induced Pluripotent Stem (IPS) Cells? - Stem Cell ... - June 5th, 2019
- Induced Pluripotent Stem Cell - ScienceDirect - June 5th, 2019
- Stem Cell Glossary A Closer Look at Stem Cells - June 2nd, 2019